The Bcl-2 Protein Family: Arbiters of Cell Survival, Science, vol.281, issue.5381, pp.1322-1326, 1998. ,
DOI : 10.1126/science.281.5381.1322
MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family, Oncogene, vol.13, issue.9, pp.1274-1279466, 2008. ,
DOI : 10.1038/onc.2008.466
Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1, Proc. Natl. Acad. Sci. USA, pp.119-126, 2012. ,
DOI : 10.1073/pnas.1119167109
ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3910, 2011. ,
DOI : 10.1182/blood-2010-11-317438
Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma, Blood, vol.100, issue.13, pp.4629-4639, 2002. ,
DOI : 10.1182/blood.V100.13.4629
A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma, Cancer Research, vol.67, issue.9, pp.4069-4078, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-3699
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients, Cancer Cell, vol.9, issue.4, pp.313-325, 2006. ,
DOI : 10.1016/j.ccr.2006.03.019
The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis, Cancer Cell, vol.11, issue.4, pp.349-360, 2007. ,
DOI : 10.1016/j.ccr.2007.02.015
AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies, Cancer Cell, vol.13, issue.2, pp.167-180, 2008. ,
DOI : 10.1016/j.ccr.2008.01.007
Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice, Journal of Clinical Investigation, vol.113, issue.12, pp.1763-1773, 2004. ,
DOI : 10.1172/JCI20369DS1
A molecular compendium of genes expressed in multiple myeloma, Blood, vol.100, issue.6, pp.2175-2186, 2002. ,
DOI : 10.1182/blood-2002-01-0008
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients, Oncotarget, vol.3, issue.4, pp.490-501481, 2012. ,
DOI : 10.18632/oncotarget.481
Comparison of Murine Leukemia Virus, Human Immunodeficiency Virus, and Adeno-Associated Virus Vectors for Gene Transfer in Multiple Myeloma: Lentiviral Vectors Demonstrate a Striking Capacity to Transduce Low-Proliferating Primary Tumor Cells, Human Gene Therapy, vol.14, issue.18, pp.1727-1739, 2003. ,
DOI : 10.1089/104303403322611746
Loss of the Pro-Apoptotic BH3-only Bcl-2 Family Member Bim Inhibits BCR Stimulation???induced Apoptosis and Deletion of Autoreactive B Cells, The Journal of Experimental Medicine, vol.160, issue.7, pp.1119-1126, 2003. ,
DOI : 10.4049/jimmunol.166.10.6025
Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells, Blood, vol.110, issue.12, pp.3978-3984, 2007. ,
DOI : 10.1182/blood-2007-05-091306
Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines, European Journal of Immunology, vol.36, issue.12, pp.3332-3340, 1997. ,
DOI : 10.1002/eji.1830271232
Bim regulates B-cell receptor-mediated apoptosis in the presence of CD40 signaling in CD40-pre-activated splenic B cells differentiating into plasma cells, International Immunology, vol.24, issue.5, pp.283-292, 2012. ,
DOI : 10.1093/intimm/dxr127
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease, Blood, vol.100, issue.13, pp.4615-4621, 2002. ,
DOI : 10.1182/blood-2002-04-1121
The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells, European Journal of Immunology, vol.379, issue.11, pp.3156-3164, 2004. ,
DOI : 10.1002/eji.200424981
Bone Disease in Multiple Myeloma, Medical Oncology, vol.23, issue.4, pp.431-441431, 2006. ,
DOI : 10.1385/MO:23:4:431
Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim sustains B lymphopoiesis in the absence of IL-7, International Immunology, vol.21, issue.6, pp.715-725, 2009. ,
DOI : 10.1093/intimm/dxp043
URL : https://hal.archives-ouvertes.fr/pasteur-00429029
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma, Nature Genetics, vol.90, issue.2, pp.226-230, 1997. ,
DOI : 10.1126/science.275.5299.540
Diva, a Bcl-2 Homologue that Binds Directly to Apaf-1 and Induces BH3-independent Cell Death, Journal of Biological Chemistry, vol.273, issue.49, pp.32479-32486, 1998. ,
DOI : 10.1074/jbc.273.49.32479
Bcl-B, a Novel Bcl-2 Family Member That Differentially Binds and Regulates Bax and Bak, Journal of Biological Chemistry, vol.276, issue.16, pp.12481-12484, 2001. ,
DOI : 10.1074/jbc.C000871200
Survival and Proliferation Factors of Normal and Malignant Plasma Cells, International Journal of Hematology, vol.276, issue.2, pp.106-113, 2003. ,
DOI : 10.1007/BF02983377
URL : https://hal.archives-ouvertes.fr/inserm-00130900
Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies, Clinical Cancer Research, vol.14, issue.10, pp.3011-3021, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1955
Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies, Blood, vol.103, issue.7, pp.2779-2786, 2004. ,
DOI : 10.1182/blood-2003-10-3399
Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma, Blood, vol.109, issue.9, pp.3849-3855, 2007. ,
DOI : 10.1182/blood-2006-11-056879
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective, The Oncologist, vol.15, issue.1, pp.6-25, 2009. ,
DOI : 10.1634/theoncologist.2009-0203
Osteoclast activity modulates B-cell development in the bone marrow, Cell Research, vol.95, issue.7, pp.1102-1115, 2011. ,
DOI : 10.1359/jbmr.1997.12.9.1335
URL : https://hal.archives-ouvertes.fr/hal-00608176
Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18), Nature, vol.349, issue.6306, pp.254-256, 1991. ,
DOI : 10.1038/349254a0
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, vol.118, issue.5, pp.1329-1339, 2011. ,
DOI : 10.1182/blood-2011-01-327197
A Novel Transgenic Mouse Model of the Human Multiple Myeloma Chromosomal Translocation t(14;16)(q32;q23), Cancer Research, vol.71, issue.2, pp.339-348, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-1057
The KDM3A???KLF2???IRF4 axis maintains myeloma cell survival, Nature Communications, vol.157, p.10258, 2016. ,
DOI : 10.1128/MCB.02154-07
Loss of the proapoptotic protein, Bim, breaks B cell anergy, The Journal of Experimental Medicine, vol.142, issue.3, pp.731-741, 2006. ,
DOI : 10.1084/jem.186.11.1923
Multiple Myeloma, New England Journal of Medicine, vol.364, issue.11, pp.1046-1060, 2011. ,
DOI : 10.1056/NEJMra1011442
URL : https://hal.archives-ouvertes.fr/hal-01282339
Insertion of c-Myc into Igh Induces B-Cell and Plasma-Cell Neoplasms in Mice, Cancer Research, vol.65, issue.4, pp.1306-1315, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-0268
The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist, Cell Death and Disease, vol.3, issue.12, 2012. ,
DOI : 10.1016/j.molcel.2005.02.003
The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma, British Journal of Haematology, vol.83, issue.2, pp.180-189, 2009. ,
DOI : 10.1111/j.1365-2141.2009.07608.x
Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity, Blood, vol.123, issue.18, pp.2806-2815, 2014. ,
DOI : 10.1182/blood-2013-08-519470
IRF4 addiction in multiple myeloma, Nature, vol.403, issue.7201, pp.226-231, 2008. ,
DOI : 10.1038/nature07064
Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells. Regulation during interleukin-6 (IL-6)-induced growth and survival, European Journal of Haematology, vol.56, issue.2, pp.76-89, 2002. ,
DOI : 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor, Blood, vol.113, issue.19, pp.4614-4626, 2009. ,
DOI : 10.1182/blood-2008-07-170464
URL : https://hal.archives-ouvertes.fr/inserm-00367812
Multiple myeloma therapies, Nature Reviews Drug Discovery, vol.30, issue.3, pp.181-182, 2007. ,
DOI : 10.1038/nrd2269
BCL?X expression in multiple my? eloma: possible indicator of chemoresistance, Cancer Res, vol.58, pp.256-262, 1998. ,
Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B, Oncogene, vol.49, issue.48, pp.5439-5448, 2013. ,
DOI : 10.1038/onc.2013.99
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.96, issue.7, pp.1248-1252, 2005. ,
DOI : 10.1093/jnci/djh122
Characterization of the anti-apoptotic mechanism of Bcl-B, Biochemical Journal, vol.376, issue.1, pp.229-236, 2003. ,
DOI : 10.1042/bj20030374
MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes, Blood, vol.97, issue.12, pp.3902-3909, 2001. ,
DOI : 10.1182/blood.V97.12.3902